Friday, May 20, 2016

Study reveals Alecensa is effective against specific type of lung cancer in Japanese patients

… or recurrent, ALK-positive non-small cell lung cancer (NSCLC).
Roche's Phase … with advanced ALK-positive non-small cell lung cancer (NSCLC), revealed a 66 percent … advancement for people with ALK-positive lung cancer, and we plan to discuss …

No comments:

Post a Comment